# A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

> **NCT06487702** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Rui-hua Xu, MD, PhD** · enrollment: 70 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium

## Key facts

- **NCT ID:** NCT06487702
- **Lead sponsor:** Rui-hua Xu, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2026-06-10
- **Final completion:** 2027-06-10
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06487702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06487702, "A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06487702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*